Why Large Companies Struggle to Innovate
The corporate innovation paradox: the large organisation has more resources, more market access, more talent, and more credibility than the startup it is often disrupted by — and yet the startup consistently outperforms the corporation in creating new business value. The explanation for this paradox is structural rather than motivational: the systems, processes, and incentives that make a large organisation excellent at its current business are the same systems, processes, and incentives that make it resistant to the exploration required to build the next business. The quarterly financial reporting cadence that disciplines current business performance punishes the early-stage losses that innovation requires; the risk management processes that protect the current business prevent the experiments that new business requires; the resource allocation processes that serve the current business starve the embryonic new business of the resources it needs to develop.
The corporate immune system concept that most accurately describes why innovation initiatives fail inside large organisations: the existing business interests, the established processes, and the career incentives of the people whose current success depends on the current business are all aligned against the new initiative that threatens to change it. The manager whose performance is measured on the current business’s results has no incentive to support an initiative that might cannibalise current revenue; the process team whose role is to ensure consistent quality in the current business has every incentive to apply those quality standards to the new initiative, making it impossible to move at the speed innovation requires.
Organisational Structures That Enable Innovation
The organisational structures that most effectively protect innovation from the corporate immune system while keeping it connected to the corporate resources that make it viable: the skunkworks (a small, physically and culturally separated team working on a specific innovation initiative with insulated resources, dedicated leadership, and protection from standard corporate processes), the corporate venture capital arm (an internal investment vehicle that funds innovation projects with defined capital allocation and venture-style governance), and the corporate incubator or accelerator (a structured programme that develops early-stage innovation initiatives through defined stages with defined investment and defined evaluation criteria).
The innovation governance structure that most effectively balances the protection that innovation needs from the corporate immune system with the accountability that a corporate innovation investment requires: the separate board or steering committee for the innovation portfolio that evaluates progress against innovation-appropriate milestones rather than current-business financial metrics. The innovation project that is evaluated on the same financial criteria as the mature business will always lose — its early-stage losses are real, while its future potential is uncertain. The innovation governance that evaluates against learning milestones, customer validation evidence, and hypothesis testing progress is the governance appropriate to the stage of the initiative.
Innovation Process: From Idea to Business
The corporate innovation process that most effectively converts the abundance of ideas that large organisations generate into the smaller number of viable new businesses that their resources can develop: the stage-gate process adapted for innovation’s specific requirements. The standard stage-gate process in most corporations is designed to manage execution risk in known business models — it evaluates whether an initiative is on time, on budget, and meeting its technical specifications. The innovation stage-gate evaluates instead whether the initiative is testing the right hypotheses, learning from those tests, and pivoting when the evidence requires it — a fundamentally different set of criteria that require a different review process and different reviewers.
The hypothesis-driven innovation process that most efficiently converts corporate resources into validated business opportunities: the explicit articulation of the specific assumptions that must be true for the initiative to become a viable business, the design of the minimum experiments that would test those assumptions with the minimum investment required to produce reliable evidence, and the disciplined evaluation of evidence against the original hypothesis rather than the motivated reasoning that seeks to confirm what the team already believes. This process is uncomfortable for corporate environments accustomed to planning for known outcomes, but it is the only process that efficiently separates the assumptions worth investing in from those worth discarding.
Culture and Leadership for Corporate Innovation
The cultural conditions that most enable corporate innovation to succeed: the explicit permission to fail on specific experiments without career consequences (which requires the senior leadership to publicly protect the careers of people who run well-designed experiments that produce negative results), the tolerance for the ambiguity and iteration that innovation requires (which requires the middle management that typically demands clarity and predictability to accept different standards for innovation initiatives), and the genuine curiosity about customers and market changes that drives the exploration orientation that innovation requires.
The senior leadership behaviour that most powerfully enables corporate innovation: the visible sponsorship of specific innovation initiatives combined with the visible protection of innovation teams from the corporate processes and pressures that would prevent them from operating at the speed and with the experimental approach that innovation requires. The executive who publicly defends an innovation team’s failure to meet a conventional reporting requirement because the team was executing a customer experiment that required more flexibility than the standard process allows is demonstrating the cultural permission that makes innovation possible. The executive who subjects the innovation team to the same processes as the mature business is guaranteeing that the innovation team will operate like the mature business — and produce nothing new.
Measuring Innovation Investment
The innovation portfolio measurement framework that most effectively reveals whether the corporate innovation investment is producing value: the three-horizon model that tracks the proportion of innovation investment allocated to horizon one (improvements to the current core business), horizon two (extensions and adjacencies that build on current capabilities), and horizon three (transformational bets on genuinely new businesses). Most corporate innovation budgets are heavily concentrated in horizon one — the safest and most familiar kind of innovation — at the expense of the horizon two and three investments that produce the future businesses that sustain the organisation’s growth over the long term.
The innovation investment return measurement that most honestly reflects what innovation investment produces: a portfolio-level return that tracks the total value created by all innovation investments over a defined period, including both the successes and the failures. The corporate innovation programme that evaluates each initiative against its individual return on investment will perpetually underinvest in innovation because every early-stage initiative will show a negative return — the value is in the portfolio, not in any individual initiative. The organisation that understands this and measures accordingly can make the portfolio-level investment decision that produces the right mix of initiatives and the portfolio-level return that justifies the investment.